Drug intelligence / Profile preview

fluorodopa

Development stage: Approved
Lead developer: Novartis
Modality: Small Molecules
Administration: Injection

Overview

Fluorodopa (F-DOPA) is a non-radioactive, fluorine-containing dopaminergic agent being investigated as a promising Fluorine-19 (19F) MRI probe. It is used to evaluate presynaptic dopaminergic function in the striatum, particularly for the early diagnosis of Parkinson's disease by detecting the loss of dopaminergic neurons. Studies in a 6-hydroxydopamine (6-OHDA)-induced hemiparkinsonian rat model showed that F-DOPA induced rotational behavior and accumulated significantly in the ipsilateral striatum after injection.

Targets

DDC (Aromatic L-amino acid decarboxylase)

Beyond the preview

Go deeper on fluorodopa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluorodopa.

Explore the full profile